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Background
Our aim is to develop replication-competent viral vectors
for mucosal delivery, which express HIV-Env immuno-
gens that closely mimic the trimeric glycoprotein spike
found on HIV particles. We have developed attenuated
recombinant CDV (rCDV) expressing SIVmac239-Env
and shown that this vector can be used safely to elicit
Env-specific immune responses in ferrets and non-human
primates through intranasal administration.
Methods
To augment the cell surface expression of trimeric HIV-
Env and increase the replicative capacity of rCDV vec-
tors encoding the HIV glycoprotein, we have con-
structed chimeric immunogens in which signal peptide
(SP), transmembrane domain (TM), or cytoplasmic tail
(CT) domains in HIV-Env have been replaced with ana-
logous sequences from the vesicular stomatitis virus
(VSV)-G or CDV-F glycoproteins and compared cell
surface protein expression, antibody binding profiles and
Env function in transient expression assays.
Results
Chimeric glycoprotein based on subtype C Env proteins
were expressed on the surface of transfected cells in
conformations recognized by various broadly neutraliz-
ing antibodies (bnAb) targeting distinct Env regions
including VRC01, b12, and b6 specific for the CD4
binding site, PG9 and PG16 (V1/V2), 4e10 (gp41) but
not by PGT-126 (V3) and 2G12 (glycans). Moreover,
treatment of transfected cells with soluble CD4 induced
conformational changes needed to expose epitopes
for CD4 binding-dependent antibodies (17b, 48d and
F425-A1g8). Recombinant CDV vectors encoding two
chimeric Envs have been created. One is expressed most
abundantly in transfected cells and contained the VSV
SP and CDV TM-CT. The second is a highly fusogenic
Env that contained the CDV SP and CDV CT. Both vec-
tors expressed Env and are being further characterized
in vitro and in vivo.
Conclusion
Collectively, we have shown CDV can be used as a
mucosal delivery vector for SIV-Env and that HIV-Env
modifications can be made that improve cell surface
expression of the trimeric glycoprotein containing struc-
tural determinants recognized by bnAbs.
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